Vince C. Biemans

Maastricht, LI, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry.

Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry.

Journal: Alimentary pharmacology & therapeutics

Published: August 02, 2022

Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.

Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.

Journal: Digestive diseases and sciences

Published: July 25, 2022

Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.

Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: January 27, 2022

Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease.

Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease.

Journal: European journal of gastroenterology & hepatology

Published: August 02, 2021

Letter: tofacitinib in treatment-refractory ulcerative colitis-a single centre real-world experience in Australia. Authors' reply.

Letter: tofacitinib in treatment-refractory ulcerative colitis-a single centre real-world experience in Australia. Authors' reply.

Journal: Alimentary pharmacology & therapeutics

Published: July 31, 2021

Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.

Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.

Journal: Journal of Crohn's & colitis

Published: April 28, 2021

Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Authors' reply.

Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Authors' reply.

Journal: Alimentary pharmacology & therapeutics

Published: October 21, 2020

Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.

Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.

Journal: Alimentary pharmacology & therapeutics

Published: October 05, 2020

Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply.

Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply.

Journal: Alimentary pharmacology & therapeutics

Published: September 05, 2020

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.

Journal: Alimentary pharmacology & therapeutics

Published: March 27, 2020

Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.

Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.

Journal: Alimentary pharmacology & therapeutics

Published: February 24, 2020

A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients.

A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients.

Journal: Alimentary pharmacology & therapeutics

Published: February 10, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026